Should sarcoidosis patients stay on infliximab? new trial aims to find out

NCT ID NCT05689879

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial looks at whether people with severe sarcoidosis who are in remission should stop or continue taking infliximab. 32 adults who have been on infliximab for at least 6 months and are stable on low-dose steroids will be randomly assigned to stop or continue the drug. The goal is to see which strategy better prevents major relapses over the next year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab (a TNF-alpha inhibitor)
What this could lead to: If successful, this could show that continuing infliximab longer helps prevent relapses in people with severe sarcoidosis.
What could go wrong: This is a small, early-stage trial with only 32 participants, so results may not apply to everyone. There is also a risk of side effects from continued infliximab use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOIDOSIS

Contacts and locations

Locations

Hôpital de la Pitié-Salpêtrière

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.